Skip to main content
Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2023 Sep 29;16:106. doi: 10.1186/s13045-023-01501-w

Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

Arnon Nagler 1,, Myriam Labopin 2,3, Didier Blaise 4, Anna Maria Raiola 5, Lucia Lopez Corral 6, Stefania Bramanti 7, Simona Sica 8,9, Mi Kwon 10, Yener Koc 11, Jiri Pavlu 12, Alexander Kulagin 13, Alessandro Busca 14, Arancha Bermúdez Rodríguez 15, Péter Reményi 16, Christoph Schmid 17, Eolia Brissot 18, Jaime Sanz 19, Ali Bazarbachi 20, Sebastian Giebel 21, Fabio Ciceri 22, Mohamad Mohty 2,3
PMCID: PMC10543832  PMID: 37775766

Correction : Journal of Hematology & Oncology (2023) 16:58 10.1186/s13045-023-01450-4

The original article [1] incorrectly presents Affiliation 7. The correct affiliation can be viewed ahead in this Correction article:

7Transplantation Unit Department of Oncology and Haematology, IRCCS Humanitas Research Hospital, Milan, Italy.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Nagler A, et al. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16:58. doi: 10.1186/s13045-023-01450-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES